Prognostic Value of Excision Repair Cross-Complementing mRNA Expression in Gastric Cancer

Table 2

The prognostic value of the mRNA expression of ERCC in different differentiation GC patients.

Genes	Differentiation	cases	HR (95% CI)	P-value
ERCC1	Poorly	165	0.7 (0.45–1.07)	0.099
	Moderately	67	1.75 (0.91–3.36)	0.09
	Well	32	1.87 (0.55–6.38)	0.31
ERCC2	Poorly	165	1.49 (0.91–2.43)	0.11
	Moderately	67	1.67 (0.85–3.3)	0.13
	Well	32	1.7 (0.68–4.23)	0.25
ERCC3	Poorly	165	1.37 (0.92–2.03)	0.12
	Moderately	67	1.39 (0.67–2.9)	0.38
	Well	32	4.15 (1.47–11.69)	0.004
ERCC4	Poorly	165	1.48 (0.94–2.33)	0.089
	Moderately	67	2.21 (1.12–4.34)	0.019
	Well	32	2.2 (0.65–7.49)	0.2
ERCC5	Poorly	165	1.26 (0.85–1.88)	0.25
	Moderately	67	0.6 (0.29–1.21)	0.15
	Well	32	1.37 (0.58–3.25)	0.47
ERCC6	Poorly	165	1.61 (1.01–2.55)	0.042
	Moderately	67	2.02 (1.05–3.88)	0.032
	Well	32	4.09 (0.95–17.66)	0.041
ERCC8	Poorly	121	1.5 (0.93–2.44)	0.097
	Moderately	67	0.53 (0.28–1.03)	0.057
	well	5

Notes. ERCC, excision repair cross-complementing; GC, gastric cancer; HR, hazard ratio; CI, confidence interval.